Kronik böbrek hastalığında inflamasyon belirteçleri ile enfeksiyon ilişkisi

Amaç: Bu çalışmada kronik böbrek hastalığı (KBH) olan hastalarda gelişen enfeksiyonların tanı ve takibinde C-reaktif protein (CRP) ve prokalsitonin (PCT)’in önemini değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışmada, Mart 2012 - Haziran 2014 tarihleri arasında Ondokuz Mayıs Üniversitesi nefroloji bölümünde yatarak tedavi gören 1538 hasta değerlendirildi. Çalışmaya herhangi bir bakteriyel enfeksiyon nedeniyle tedavi almış ve tüm verileri eksiksiz olan 72 KBH (Glomerüler filtrasyon hızı

Relationship between inflammatory markers and infection in chronic kidney disease

Purpose: The aim of this study was to evaluate the importance of C-reactive protein (CRP) and procalcitonin (PCT) in the diagnosis and monitoring of infections in chronic kidney disease (CKD) patients. Materials and Methods: In this study, 1538 hospitalized patients in the nephrology division of Ondokuz Mayıs University between March 2012 and June 2014 were evaluated. A total of 72 patients with CKD (Glomerular filtration rate

Keywords:

Chronic kidney disease C-reactive protein, procalcitonin, infection,

PDF

___

1. Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol. 2019;23:437–47.
2. Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets. 2009;8:369–82
3. Rojas L, Muñoz P, Kestler M, Arroyo D, Guembe M, Rodríguez-Créixems M et al. Bloodstream infections in patients with kidney disease: risk factors for poor outcome and mortality. J Hosp Infect. 2013;85:196– 205.
4. Hildebrand A. Komenda P, Miller L, Rigatto C, Verrelli M, Sood AR et al. Peritonitis and exit site infections in first nations patients on peritoneal dialysis. Clin J Am Soc Nephrol. 2010;5:1988–95.
5. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M et al. C reactive protein in patients with chronic renal diseases. Ren Fail. 2001;23:551–62.
6. Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol. 2007;2:872–5.
7. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–17.
8. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med. 2007;50:34–41.
9. Guz G, Colak B, Hizel K, Reis KA, Erten Y, Bali M et al. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. Perit Dial Int. 2006;26:240–8.
10. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitoninguided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37:497–507.
11. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79:1605–8.
12. Pepys MB, Hirschfield GM. C-rective protein: a critical update. J Clin Invest. 2003;111:1805–12.
13. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17:1–59.
14. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG et al. International clinical practice guidelines for the treatment of acute uncomplicatedmcystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:103– 20.
15. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE , Gupta A et al. Peritoneal dialysis–related infections recommendations: 2010 update. Perit Dial Int 2010;30:393–423. 16.
16. Çetinkaya ŞY, Güner R, Çakar N, Ağalar F, Bolaman Z, Yavaşoğlu İ et al. Damar Hastane İnfeksiyonları Dergisi. 2013;17:233–79.
17. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2013;39:165–228.
18. Paolucci M, Landini MP, Sambri V. Conventional and molecular techniques for the early diagnosis of bacteraemia. Int J Antimicrob Agents. 2010;36:6–16.
19. Lu X-L, Xiao ZH, Yang MY, Zhu YM. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and metaanalysis. Nephrol Dial Transplant. 2012;28:122–9.
20. Meisner M. Procalcitonin: a new innovative infection parameter. 3rd ed. Stuttgart: Brahms Diagnostica. 2000.
21. van Rossum AMC, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. Lancet Inf Dis. 2004;4:620–30.
22. Oczenski W, Fitzgerald RD, Schwarz S. Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period. Eur J Anaesthesiol. 1998;15:202–9.
23. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol. 2000;53:452–9.
24. Steinbach G, Bölke E, Grünert A, Orth K, Störck M. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr. 2004;116: 849– 53.
25. Park JH, Kim DH, Jang HR, Kim MJ, Jung SH, Lee JE, et al. Clinical relevance of procalcitonin and Creactive protein as infection markers in renal impairment: a cross-sectional study. Critical Care. 2014;18(6):640.
26. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. CReactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35(3):469–76.
27. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002; 62:1417–22.
28. Herget-Rosental S, Marggraf G, Pietruck F, Hüsing J, Strupat M, Philipp T, et al. Procalcitonin for accurate of infection in haemodialysis. Nephrol Dial Transplant. 2001;16;975–9.
29. Lavin Gomez et al. Palomar-Fontanet R, Gago-Fraile M, Quintanar-Lartundo JA, Gómez-Palomo E, González-Lamuño D. Inflammation markers, chronic kidney disease, and renal replacement therapy Adv Perit Dial. 2011;27:33–7.
30. Lee J, Hwang SS, Kim K, Jo YH, Lee JH, Kim J et al. Bacteremia prediction model using a common clinical test in patients with community-acquired pneumonia. Am J Emerg Med. 2014;32:700–4.
31. Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients Int Urol Nephrol. 2014;46:461–8.
32. Oksuz L, Somer A, Salman N, Erk O, Gurler N. Procalcitonin and C-reactive protein in differantiating to contamination from bacteremia. Brazilian Journal of Microbiology. 2014;45:1415–21.
33. Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection. 2007;35:352–5.
34. Jeong S, Park Y, Cho Y, Kim HS. Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture. Clin Chim Acta. 2012;413:1731–6.